查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1968155

全球誘導多功能細胞生產市場規模、佔有率、趨勢和成長分析報告（2026-2034）

Global Induced Pluripotent Stem Cells Production Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計誘導多功能細胞生產市場將從 2025 年的 17,875.8 億美元成長到 2034 年的 4,1499.4 億美元，2026 年至 2034 年的複合年成長率為 9.81%。

由於人們對再生醫學和細胞療法的興趣日益濃厚，全球誘導多功能細胞（iPS細胞）市場正經歷顯著成長。 iPS細胞是將成體細胞重編程為胚胎樣的狀態，並且能夠分化成多種細胞類型。這項技術在疾病建模、藥物篩檢和組織再生方面具有巨大的潛力。幹細胞生物學研究的日益活躍以及慢性疾病盛行率的上升正在推動市場的發展。

推動該市場發展的主要因素是iPS細胞在個人化醫療和先進治療方法開發中的應用日益廣泛。製藥公司利用iPS細胞測試藥物的毒性和療效，降低後期臨床試驗失敗的風險。政府的支持性法規、資助計畫以及研究機構與生技公司之間的合作也促進了產能的提升。重編程技術的進步使整個過程更加高效且經濟。

隨著幹細胞療法臨床試驗的增加，預計未來市場將快速成長。自動化生產系統和標準化通訊協定的開發將進一步提升規模化生產能力。亞太地區生物技術基礎設施的不斷完善，使其成為一個極具潛力的市場。隨著再生醫學的普及，誘導多能幹細胞（iPS細胞）生產市場有望實現持續的長期成長和創新。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球誘導性多功能細胞生產市場：依製程分類

  • 市場分析、洞察與預測
  • 手動iPS細胞生產過程
  • 自動化iPS細胞生產流程

第5章 全球誘導性多功能細胞生產市場：依工作流程分類

  • 市場分析、洞察與預測
  • 再程式化
  • 細胞培養
  • 細胞表徵/分析
  • 工程
  • 其他

第6章 全球誘導性多功能細胞生產市場：依產品分類

  • 市場分析、洞察與預測
  • 設備/器材
  • 自動化平台
  • 耗材和工具包
  • 服務

第7章 全球誘導性多功能細胞生產市場：依應用分類

  • 市場分析、洞察與預測
  • 藥物研發和藥物發現
  • 再生醫學
  • 毒理學測試
  • 其他

第8章 誘導多功能細胞生產的全球市場：依最終用途分類

  • 市場分析、洞察與預測
  • 研究和學術機構
  • 生物技術和製藥公司
  • 醫院和診所

第9章 全球誘導性多功能細胞生產市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第10章 競爭格局

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第11章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Lonza
    • Axol Bioscience Ltd
    • Evotec
    • Hitachi Ltd
    • Reprocell Inc
    • Merck KGaA
    • Reprocells Inc
    • Fate Therapeutics
    • Thermo Fisher Scientific Inc
    • StemCellsFactory III
    • Applied StemCells Inc
簡介目錄
Product Code: VMR112110349

The Induced Pluripotent Stem Cells Production Market size is expected to reach USD 4149.94 Billion in 2034 from USD 1787.58 Billion (2025) growing at a CAGR of 9.81% during 2026-2034.

The Global Induced Pluripotent Stem Cells (iPSCs) Production Market is witnessing strong growth due to rising interest in regenerative medicine and cell-based therapies. iPSCs are adult cells that are reprogrammed to an embryonic-like state, allowing them to differentiate into various cell types. This technology offers significant potential in disease modeling, drug screening, and tissue regeneration. Increasing research activities in stem cell biology and the growing prevalence of chronic diseases are driving the market forward.

A major driver for this market is the expanding application of iPSCs in personalized medicine and advanced therapeutic development. Pharmaceutical companies are using iPSCs to test drug toxicity and efficacy, reducing the risk of failure in later clinical stages. Supportive government regulations, funding programs, and partnerships between research institutes and biotech firms are also accelerating production capabilities. Technological improvements in reprogramming methods have made the process more efficient and cost-effective.

Looking ahead, the market is expected to grow rapidly with increasing clinical trials involving stem cell therapies. The development of automated production systems and standardized protocols will further enhance scalability. Asia-Pacific is emerging as a strong region due to expanding biotechnology infrastructure. As regenerative medicine becomes more mainstream, the iPSCs production market is likely to see sustained long-term growth and innovation.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Process

  • Manual iPSC Production Process
  • Automated iPSC Production Process

By Workflow

  • Reprogramming
  • Cell Culture
  • Cell Characterization/Analysis
  • Engineering
  • Others

By Product

  • Instruments/Devices
  • Automated Platforms
  • Consumables & Kits
  • Services

By Application

  • Drug Development & Discovery
  • Regenerative Medicine
  • Toxicology Studies
  • Others

By End Use

  • Research & Academic Institutes
  • Biotechnology & Pharmaceutical Companies
  • Hospitals & Clinics

COMPANIES PROFILED

  • Lonza, Axol Bioscience Ltd, Evotec, Hitachi Ltd, Reprocell Inc, Merck KGaA, Reprocells Inc, Fate Therapeutics, Thermo Fisher Scientific Inc, StemCellsFactory III, Applied StemCells Inc
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL INDUCED PLURIPOTENT STEM CELLS PRODUCTION MARKET: BY PROCESS 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Process
  • 4.2. Manual iPSC Production Process Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Automated iPSC Production Process Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL INDUCED PLURIPOTENT STEM CELLS PRODUCTION MARKET: BY WORKFLOW 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Workflow
  • 5.2. Reprogramming Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Cell Culture Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Cell Characterization/Analysis Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Engineering Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL INDUCED PLURIPOTENT STEM CELLS PRODUCTION MARKET: BY PRODUCT 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Product
  • 6.2. Instruments/Devices Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Automated Platforms Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Consumables & Kits Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.5. Services Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL INDUCED PLURIPOTENT STEM CELLS PRODUCTION MARKET: BY APPLICATION 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast Application
  • 7.2. Drug Development & Discovery Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Regenerative Medicine Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.4. Toxicology Studies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL INDUCED PLURIPOTENT STEM CELLS PRODUCTION MARKET: BY END USE 2022-2034 (USD MN)

  • 8.1. Market Analysis, Insights and Forecast End Use
  • 8.2. Research & Academic Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.3. Biotechnology & Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.4. Hospitals & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL INDUCED PLURIPOTENT STEM CELLS PRODUCTION MARKET: BY REGION 2022-2034(USD MN)

  • 9.1. Regional Outlook
  • 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.2.1 By Process
    • 9.2.2 By Workflow
    • 9.2.3 By Product
    • 9.2.4 By Application
    • 9.2.5 By End Use
    • 9.2.6 United States
    • 9.2.7 Canada
    • 9.2.8 Mexico
  • 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.3.1 By Process
    • 9.3.2 By Workflow
    • 9.3.3 By Product
    • 9.3.4 By Application
    • 9.3.5 By End Use
    • 9.3.6 United Kingdom
    • 9.3.7 France
    • 9.3.8 Germany
    • 9.3.9 Italy
    • 9.3.10 Russia
    • 9.3.11 Rest Of Europe
  • 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.4.1 By Process
    • 9.4.2 By Workflow
    • 9.4.3 By Product
    • 9.4.4 By Application
    • 9.4.5 By End Use
    • 9.4.6 India
    • 9.4.7 Japan
    • 9.4.8 South Korea
    • 9.4.9 Australia
    • 9.4.10 South East Asia
    • 9.4.11 Rest Of Asia Pacific
  • 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.5.1 By Process
    • 9.5.2 By Workflow
    • 9.5.3 By Product
    • 9.5.4 By Application
    • 9.5.5 By End Use
    • 9.5.6 Brazil
    • 9.5.7 Argentina
    • 9.5.8 Peru
    • 9.5.9 Chile
    • 9.5.10 South East Asia
    • 9.5.11 Rest of Latin America
  • 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.6.1 By Process
    • 9.6.2 By Workflow
    • 9.6.3 By Product
    • 9.6.4 By Application
    • 9.6.5 By End Use
    • 9.6.6 Saudi Arabia
    • 9.6.7 UAE
    • 9.6.8 Israel
    • 9.6.9 South Africa
    • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

  • 10.1. Recent Developments
  • 10.2. Company Categorization
  • 10.3. Supply Chain & Channel Partners (based on availability)
  • 10.4. Market Share & Positioning Analysis (based on availability)
  • 10.5. Vendor Landscape (based on availability)
  • 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL INDUCED PLURIPOTENT STEM CELLS PRODUCTION INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Company Profiles
    • 11.2.1 Lonza
    • 11.2.2 Axol Bioscience Ltd
    • 11.2.3 Evotec
    • 11.2.4 Hitachi Ltd
    • 11.2.5 Reprocell Inc
    • 11.2.6 Merck KGaA
    • 11.2.7 Reprocells Inc
    • 11.2.8 Fate Therapeutics
    • 11.2.9 Thermo Fisher Scientific Inc
    • 11.2.10 StemCellsFactory III
    • 11.2.11 Applied StemCells Inc